Idexx Laboratories (IDXX) Non-Current Deffered Revenue (2009 - 2026)

Idexx Laboratories (IDXX) has reported Non-Current Deffered Revenue for 18 consecutive years, with $32.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 20.49% year-over-year to $32.3 million; the TTM figure through Mar 2026 stood at $32.3 million (up 20.49% YoY), while the FY2025 annual figure was $32.2 million, up 19.44% from the prior year.
• Non-Current Deffered Revenue came in at $32.3 million for Q1 2026 at Idexx Laboratories, roughly flat from $32.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $39.2 million in Q1 2022, with the low at $26.8 million in Q3 2024.
• Average Non-Current Deffered Revenue over 5 years is $30.6 million, with a median of $30.4 million recorded in 2023.
• Across the five-year window, Non-Current Deffered Revenue fell 25.04% in 2022 and grew 20.49% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $30.9 million in 2022, then decreased by 7.55% to $28.5 million in 2023, then slipped by 5.59% to $26.9 million in 2024, then gained by 19.44% to $32.2 million in 2025, then rose by 0.42% to $32.3 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $32.3 million, $32.2 million, and $31.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.